Controlling aberrant RAS signaling has been the subject of intensive efforts aimed at developing specific RAS inhibitors, small molecules that promote RAS degradation, and monobodies that inhibit RAS activity. Direct proteolytic degradation of RAS by site-specific proteases has received considerably less attention. A n...
T. Fuerst, M. Goldstein, Betty W. Chu et al.· Research Square· 0 citations
These studies show that a well-characterized sE1E2 platform compatible with multiple genotypes can be coupled to nanoparticles for use as a vaccine candidate and sets the stage for further exploration of nanoparticles and other multivalent platforms for the development of E1E2-based vaccines.
Liudmila Kulakova, Sarah Jeong, Dong-Xiu Zhang et al.· bioRxiv· 0 citations
Describing the genetic, structural, functional, and epitope features of 25 BD-directed nAbs isolated from HCV-infected individuals or immunized macaques underscores BD as a promising target for rational HCV vaccine design.
Fang Chen, Yen Thi Kim Nguyen, Yi-Zong Lee et al.· Cell Reports· 0 citations
The preclinical development of a novel HCV vaccine candidate engineered by formulating a novel native-like secreted E1E2 immunogen and a well-established combinatorial adjuvant of QS-21 + 3D-(6-acyl) PHAD into unique microneedle patches (MNPs).
Yi-Nuo Zhang, A. Dhayani, Stephen C. Balmert et al.· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
